Antibody Response After Single H1N1 Influenza Vaccine in Chronic Dialysis Patients

Department of Nephrology, Ankara Education and Research Hospital Department of Virology, Refik Saydam National Public Health Agency, Ankara, Turkey.
Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Impact Factor: 1.53). 02/2013; 17(1):55-9. DOI: 10.1111/j.1744-9987.2012.01133.x
Source: PubMed

ABSTRACT The first influenza pandemic of this century happened through a rapid spread of a novel swine-derived H1N1 influenza virus. Vaccines are produced in order to avoid the infection. Children and other high risk groups are highly recommended for vaccination due to the high probability of contracting the virus. Chronic kidney disease patients were also accepted as a risk group and vaccination of all patients undergoing hemodialysis or peritoneal dialysis was recommended. The results of H1N1 influenza virus vaccine on patients receiving hemodialysis and peritoneal dialysis are analyzed. Antibody titers of both hemodialysis and peritoneal dialysis patients were elevated after vaccination. Peritoneal dialysis patients responded better.

Download full-text


Available from: Alper Azak, Aug 14, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infections are an important cause of morbidity and mortality among patients at all stages of chronic kidney disease. Prevention through vaccination remains the best strategy to minimize the adverse consequences associated with these infectious diseases in this, and all, populations. Unfortunately, patients with chronic kidney disease demonstrate inadequacies of specific immune-cell function that are required for generating a protective vaccine response. Nevertheless, early vaccination of this high-risk population has demonstrated good clinical outcomes during progression to late-stage disease. We review the available evidence linking immune impairment in adult patients with late-stage chronic kidney disease to diminished vaccine responses. We highlight the importance of early vaccination in disease with high risk for development of CKD and novel vaccine approaches in development that may help to address improvement in protective boosting of immunity during late-stage disease.
    Expert Review of Vaccines 01/2014; 13(2). DOI:10.1586/14760584.2014.874950 · 4.22 Impact Factor